Efflux and uptake transporters as determinants of statin response

Bibliography

• Brugts JJ, Yetgin T, Hoeks SE, The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials. BMJ 2009;338:b2376
   PubMed Web of Science ®Google Scholar
• Wang CY, Liao JK. Current advances in statin treatment: from molecular mechanisms to clinical practice. Arch Med Sci 2007;3(4A):S91-6
   Web of Science ®Google Scholar
• Shitara Y, Sugiyama Y. Pharmacokinetic and pharmacodynamic alterations of 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase inhibitors: drug-drug interactions and interindividual differences in transporter and metabolic enzyme functions. Pharmacol Ther 2006;112:71-105
   PubMed Web of Science ®Google Scholar
• Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005;204:216-37
   PubMed Web of Science ®Google Scholar
• Dobson PD, Kell DB. Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat Rev Drug Discov 2008;7:205-20
   PubMed Web of Science ®Google Scholar
• Thompson PD, Clarkson P, Karas RH. Statin-associated myopathy. J Am Med Assoc 2003;289:1681-90
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ, Niemi M, Backman JT. Drug interactions with lipid-lowering drugs: mechanisms and clinical relevance. Clin Pharmacol Ther 2006;80:565-81
   PubMed Web of Science ®Google Scholar
• Hermann M, Bogsrud MP, Molden E, Exposure of atorvastatin is unchanged but lactone and acid metabolites are increased several-fold in patients with atorvastatin-induced myopathy. Clin Pharmacol Ther 2006;79:532-9
   PubMed Web of Science ®Google Scholar
• Knauer MJ, Urquhart BL, Meyer Zu Schwabedissen HE, Human skeletal muscle drug transporters determine local exposure and toxicity of statins. Circ Res 2010;106:297-306
   PubMed Web of Science ®Google Scholar
• Kerb R. Implications of genetic polymorphisms in drug transporters for pharmacotherapy. Cancer Lett 2006;234:4-33
   PubMed Web of Science ®Google Scholar
• Cascorbi I, Haenisch S. Pharmacogenetics of ATP-binding cassette transporters and clinical implications. Methods Mol Biol 2010;596:95-121
   PubMedGoogle Scholar
• Niemi M. Role of OATP transporters in the disposition of drugs. Pharmacogenomics 2007;8:787-802
   PubMed Web of Science ®Google Scholar
• Seithel A, Glaeser H, Fromm MF, The functional consequences of genetic variations in transporter genes encoding human organic anion-transporting polypeptide family members. Expert Opin Drug Metab Toxicol 2008;4:51-64
   PubMed Web of Science ®Google Scholar
• Tall AR. Cholesterol efflux pathways and other potential mechanisms involved in the athero-protective effect of high density lipoproteins. J Intern Med 2008;263:256-73
   PubMed Web of Science ®Google Scholar
• Tabas I. Consequences and therapeutic implications of macrophage apoptosis in atherosclerosis: the importance of lesion stage and phagocytic efficiency. Arterioscler Thromb Vasc Biol 2005;25:2255-64
   PubMed Web of Science ®Google Scholar
• Yvan-Charvet L, Wang N, Tall AR. Role of HDL, ABCA1, and ABCG1 transporters in cholesterol efflux and immune responses. Arterioscler Thromb Vasc Biol 2010;30:139-43
   PubMed Web of Science ®Google Scholar
• Wang N, Lan D, Chen W, ATP-binding cassette transporters G1 and G4 mediate cellular cholesterol efflux to high-density lipoproteins. Proc Natl Acad Sci USA 2004;101:9774-79
   PubMed Web of Science ®Google Scholar
• Wang X, Collins HL, Ranalletta M, Macrophage ABCA1 and ABCG1, but not SR-BI, promote macrophage reverse cholesterol transport in vivo. J Clin Invest 2007;117:2216-24
   PubMed Web of Science ®Google Scholar
• Yvan-Charvet L, Ranalletta M, Wang N, Combined deficiency of ABCA1 and ABCG1 promotes foam cell accumulation and accelerates atherosclerosis in mice. J Clin Invest 2007;117:3900-08
   PubMed Web of Science ®Google Scholar
• Out R, Jessup W, Le Goff W, Coexistence of foam cells and hypocholesterolemia in mice lacking the ABC transporters A1 and G1. Circ Res 2008;102:113-20
   PubMed Web of Science ®Google Scholar
• Brooks-Wilson A, Marcil M, Clee SM, Mutations in ABC1 in Tangier disease and familial high-density lipoprotein deficiency. Nat Genet 1999;22:336-45
   PubMed Web of Science ®Google Scholar
• Marcil M, Brooks-Wilson A, Clee SM, Mutations in the ABC1 gene in familial HDL deficiency with defective cholesterol efflux. Lancet 1999;354:1341-6
   PubMed Web of Science ®Google Scholar
• Wang CY, Liu PY, Liao JK. Pleiotropic effects of statin therapy: molecular mechanisms and clinical results. Trends Mol Med 2008;14:37-44
   PubMed Web of Science ®Google Scholar
• Forman BM, Ruan B, Chen J, The orphan nuclear receptor LXRalpha is positively and negatively regulated by distinct products of mevalonate metabolism. Proc Natl Acad Sci USA 1997;94:10588-93
   PubMed Web of Science ®Google Scholar
• Gan X, Kaplan R, Menke JG, Dual mechanisms of ABCA1 regulation by geranylgeranyl pyrophosphate. J Biol Chem 2001;276:48702-8
   PubMed Web of Science ®Google Scholar
• Schwartz K, Lawn RM, Wade DP. ABC1 gene expression and ApoA-I-mediated cholesterol efflux are regulated by LXR. Biochem Biophys Res Commun 2000;274:794-802
   PubMed Web of Science ®Google Scholar
• Venkateswaran A, Laffitte BA, Joseph SB, Control of cellular cholesterol efflux by the nuclear oxysterol receptor LXRalpha. Proc Natl Acad Sci USA 2000;97:12097-102
   PubMed Web of Science ®Google Scholar
• Venkateswaran A, Repa JJ, Lobaccaro JMA, Human white/murine ABC8 mRNA levels are highly induced in lipid-loaded macrophages. J Biol Chem 2000;275:14700-07
   PubMed Web of Science ®Google Scholar
• Laffitte BA, Joseph SB, Walczak R, Autoregulation of the human liver X receptor promoter. Mol Cell Biol 2001;21:7558-68
   PubMed Web of Science ®Google Scholar
• Wong J, Quinn CM, Brown AJ. Statins inhibit synthesis of an oxysterol ligand for the liver x receptor in human macrophages with consequences for cholesterol flux. Arterioscler Thromb Vasc Biol 2004;24:2365-71
   PubMed Web of Science ®Google Scholar
• Wong J, Quinn CM, Gelissen IC, The effect of statins on ABCA1 and ABCG1 expression in human macrophages is influenced by cellular cholesterol levels and extent of differentiation. Atherosclerosis 2008;196:180-9
   PubMed Web of Science ®Google Scholar
• Qiu G, Hill JS. Atorvastatin inhibits ABCA1 expression and cholesterol efflux in THP-1 macrophages by an LXR-dependent pathway. J Cardiovasc Pharmacol 2008;51:388-95
   PubMed Web of Science ®Google Scholar
• Staud F, Ceckova M, Micuda S, Expression and function of p-glycoprotein in normal tissues: effect on pharmacokinetics. Methods Mol Biol 2010;596:199-222
   PubMedGoogle Scholar
• Keskitalo JE, Kurkinen KJ, Neuvoneni PJ, ABCB1 haplotypes differentially affect the pharmacokinetics of the acid and lactone forms of simvastatin and atorvastatin. Clin Pharmacol Ther 2008;84:457-61
   PubMed Web of Science ®Google Scholar
• Keskitalo JE, Kurkinen KJ, Neuvonen M, No significant effect of ABCB1 haplotypes on the pharmacokinetics of fluvastatin, pravastatin, lovastatin, and rosuvastatin. Br J Clin Pharmacol 2009;68:207-13
   PubMed Web of Science ®Google Scholar
• Oswald S, Haenisch S, Fricke C, Intestinal expression of P-glycoprotein (ABCB1), multidrug resistance associated protein 2 (ABCC2), and uridine diphosphate-glucuronosyltransferase 1A1 predicts the disposition and modulates the effects of the cholesterol absorption inhibitor ezetimibe in humans. Clin Pharmacol Ther 2006;79:206-17
   PubMed Web of Science ®Google Scholar
• Yamasaki D, Nakamura T, Okamura N, Effects of acid and lactone forms of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on the induction of MDR1 expression and function in LS180 cells. Eur J Pharm Sci 2009;37:126-32
   PubMed Web of Science ®Google Scholar
• Rodrigues AC, Curi R, Genvigir FD, The expression of efflux and uptake transporters are regulated by statins in Caco-2 and HepG2 cells. Acta Pharmacol Sin 2009;30:956-64
   PubMed Web of Science ®Google Scholar
• Pfrunder A, Gutmann H, Beglinger C, Gene expression of CYP3A4, ABC-transporters (MDR1and MRP1–MRP5) and hPXR in three different human colon carcinoma cell lines. J Pharm Pharmacol 2003;55:59-66
   PubMed Web of Science ®Google Scholar
• Chen C, Lin J, Smolarek T, P-glycoprotein has differential effects on the disposition of statin acid and lactone forms in mdr1a/b knockout and wild-type mice. Drug Metab Dispos 2007;35:1725-9
   PubMed Web of Science ®Google Scholar
• Thompson JF, Man M, Johnson KJ, An association study of 43 SNPs in 16 candidate genes with atorvastatin response. Pharmacogenomics J 2005;5:352-8
   PubMed Web of Science ®Google Scholar
• Mega JL, Morrow DA, Brown A, Identification of genetic variants associated with response to statin therapy. Arterioscler Thromb Vasc Biol 2009;29:1310-5
   PubMed Web of Science ®Google Scholar
• Fiegenbaum M, da Silveira FR, Van der Sand CR, The role of common variants of ABCB1, CYP3A4, and CYP3A5 genes in lipid-lowering efficacy and safety of simvastatin treatment. Clin Pharmacol Ther 2005;78:551-8
   PubMed Web of Science ®Google Scholar
• Leslie EM, Deeley RG, Cole SP. Multidrug resistance proteins: role of P-glycoprotein, MRP1, MRP2, and BCRP (ABCG2) in tissue defense. Toxicol Appl Pharmacol 2005;204:216-37
   PubMed Web of Science ®Google Scholar
• Rebecchi IM, Rodrigues AC, Arazi SS, ABCB1 and ABCC1 expression in peripheral mononuclear cells is influenced by gene polymorphisms and atorvastatin treatment. Biochem Pharmacol 2009;77:66-75
   PubMed Web of Science ®Google Scholar
• Keitel V, Kartenbeck J, Nies AT, Impaired protein maturation of the conjugate export pump multidrug resistance protein 2 as a consequence of a deletion mutation in Dubin-Johnson syndrome. Hepatology 2000;32:1317-28
   PubMed Web of Science ®Google Scholar
• Hashimoto K, Uchiumi T, Konno T, Trafficking and functional defects by mutations of the ATP-binding domains in MRP2 in patients with Dubin-Johnson syndrome. Hepatology 2002;36:1236-45
   PubMed Web of Science ®Google Scholar
• Keitel V, Nies AT, Brom M, A common Dubin-Johnson syndrome mutation impairs protein maturation and transport activity of MRP2 (ABCC2). Am J Physiol Gastrointest Liver Physiol 2003;284:G165-74
   PubMed Web of Science ®Google Scholar
• Niemi M, Arnold KA, Backman JT, Association of genetic polymorphism in ABCC2 with hepatic multidrug resistance-associated protein 2 expression and pravastatin pharmacokinetics. Pharmacogenet. Genomics 2006;16:801-8
   Web of Science ®Google Scholar
• Bernsdorf A, Giessmann T, Modess C, Simvastatin does not influence the intestinal P-glycoprotein and MPR2, and the disposition of talinolol after chronic medication in healthy subjects genotyped for the ABCB1, ABCC2 and SLCO1B1 polymorphisms. Br J Clin Pharmacol 2006;61:440-50
   PubMed Web of Science ®Google Scholar
• Hirano M, Maeda K, Matsushima S, Involvement of BCRP (ABCG2) in the biliary excretion of pitavastatin. Mol Pharmacol 2005;68:800-7
   PubMed Web of Science ®Google Scholar
• Huang L, Wang Y, Grimm S. ATP-dependent transport of rosuvastatin in membrane vesicles expressing breast cancer resistance protein. Drug Metab Dispos 2006;34:738-42
   PubMed Web of Science ®Google Scholar
• Kondo C, Suzuki H, Itoda M, Functional analysis of SNPs variants of BCRP/ABCG2. Pharm Res 2004;21:1895-903
   PubMed Web of Science ®Google Scholar
• Morisaki K, Robey RW, Ozvegy-Laczka C, Single nucleotide polymorphisms modify the transporter activity of ABCG2. Cancer Chemother Pharmacol 2005;56:161-72
   PubMed Web of Science ®Google Scholar
• Sparreboom A, Loos WJ, Burger H, Effect of ABCG2 genotype on the oral bioavailability of topotecan. Cancer Biol Ther 2005;4:650-8
   PubMed Web of Science ®Google Scholar
• Zhang W, Yu BN, He YJ, Role of BCRP 421C>A polymorphism on rosuvastatin pharmacokinetics in healthy Chinese males. Clin Chim Acta 2006;373:99-103
   PubMed Web of Science ®Google Scholar
• Keskitalo JE, Zolk O, Fromm MF, ABCG2 polymorphism markedly affects the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2009;86:197-203
   PubMed Web of Science ®Google Scholar
• Berge KE, Tian H, Graf GA, Accumulation of dietary cholesterol in sitosterolemia caused by mutations in adjacent ABC transporters. Science 2000;290:1771-5
   PubMed Web of Science ®Google Scholar
• Berge KE, von Bergmann K, Lutjohann D, Heritability of plasma noncholesterol sterols and relationship to DNA sequence polymorphism in ABCG5 and ABCG8. J Lipid Res 2002;43:486-94
   PubMed Web of Science ®Google Scholar
• Kajinami K, Brousseau ME, Ordovas JM, Interactions between common genetic polymorphisms in ABCG5/G8 and CYP7A1 on LDL cholesterol-lowering response to atorvastatin. Atherosclerosis 2004;175:287-93
   PubMed Web of Science ®Google Scholar
• Tang W, Ma Y, Yu L. Plasma cholesterol is hyperresponsive to statin in ABCG5/ABCG8 transgenic mice. Hepatology 2006;44:1259-66
   PubMed Web of Science ®Google Scholar
• Lee W, Glaeser H, Smith LH, Polymorphisms in human organic anion-transporting polypeptide 1A2 (OATP1A2): implications for altered drug disposition and central nervous system drug entry. J Biol Chem 2005;280:9610-7
   PubMed Web of Science ®Google Scholar
• Ho RH, Tirona RG, Leake BF, Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 2006;130:1793-806
   PubMed Web of Science ®Google Scholar
• Kullak-Ublick GA, Ismair MG, Stieger B, Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 2001;120:525-33
   PubMed Web of Science ®Google Scholar
• Glaeser H, Bailey DG, Dresser GK, Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin Pharmacol Ther 2007;81:362-70
   PubMed Web of Science ®Google Scholar
• Nishizato Y, Ieiri I, Suzuki H, Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin Pharmacol Ther 2003;73:554-65
   PubMed Web of Science ®Google Scholar
• Niemi M, Schaeffeler E, Lang T, High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 2004;14:429-40
   PubMedGoogle Scholar
• Chung JY, Cho JY, Yu KS, Effect of OATP1B1 ( SLCO1B1) variants on the pharmacokinetics of pitavastatin in healthy volunteers. Clin Pharmacol Ther 2005;78:342-50
   PubMed Web of Science ®Google Scholar
• Niemi M, Pasanen MK, Neuvonen PJ. SLCO1B1 polymorphisms and sex affect the pharmacokinetics of pravastatin but not fluvastatin. Clin Pharmacol Ther 2006;80:356-66
   PubMed Web of Science ®Google Scholar
• Pasanen MK, Fredrikson H, Neuvonen PJ, Different effects of SLCO1B1 polymorphisms on the pharmacokinetics of atorvastatin and rosuvastatin. Clin Pharmacol Ther 2007;82:726-33
   PubMed Web of Science ®Google Scholar
• Tirona RG, Leake BF, Merino G, Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European- and African-Americans. J Biol Chem 2001;276:35669-75
   PubMed Web of Science ®Google Scholar
• Mwinyi J, Johne A, Bauer S, Evidence for inverse effects of OATP-C (SLC21A6) *5 and *1b haplotypes on pravastatin kinetics. Clin Pharmacol Ther 2004;75:415-21
   PubMed Web of Science ®Google Scholar
• Couvert P, Giral P, Dejager S, Association between a frequent allele of the gene encoding OATP1B1 and enhanced LDL-lowering response to fluvastatin therapy. Pharmacogenomics 2008;9:1217-27
   PubMed Web of Science ®Google Scholar
• Oswald S, König J, Lütjohann D, Disposition of ezetimibe is influenced by polymorphisms of the hepatic uptake carrier OATP1B1. Pharmacogenet Genomics 2008;18:559-68
   PubMed Web of Science ®Google Scholar
• Link E, Parish S, Armitage J, ; SEARCH collaborative group. SLCO1B1 variants and statin-induced myopathy–a genomewide study. N Engl J Med 2008;359:789-99
   PubMed Web of Science ®Google Scholar
• Voora D, Shah SH, Spasojevic I, The SLCO1B1*5 genetic variant is associated with statin-induced side effects. J Am Coll Cardiol 2009;54:1609-16
   PubMed Web of Science ®Google Scholar
• Fujino H, Saito T, Ogawa S, Transporter-mediated influx and efflux mechanisms of pitavastatin, a new inhibitor of HMG-CoA reductase. J Pharm Pharmacol 2005;57:1305-11
   PubMed Web of Science ®Google Scholar
• Noé J, Portmann R, Brun ME, Substrate-dependent drug-drug interactions between gemfibrozil, fluvastatin and other organic anion-transporting peptide (OATP) substrates on OATP1B1, OATP2B1, and OATP1B3. Drug Metab Dispos 2007;35:1308-14
   PubMed Web of Science ®Google Scholar
• Kitamura S, Maeda K, Wang Y, Involvement of multiple transporters in the hepatobiliary transport of rosuvastatin. Drug Metab Dispos 2008;36:2014-23
   PubMed Web of Science ®Google Scholar
• Letschert K, Keppler D, König J. Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATP1B3 (OATP8). Pharmacogenetics 2004;14:441-52
   PubMedGoogle Scholar
• Kobayashi D, Nozawa T, Imai K, Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther 2003;306:703-8
   PubMed Web of Science ®Google Scholar
• Grube M, Kock K, Oswald S, Organic anion transporting polypeptide 2B1 is a high-affinity transporter for atorvastatin and is expressed in the human heart. Clin Pharmacol Ther 2006;80:607-20
   PubMed Web of Science ®Google Scholar
• Nozawa T, Nakajima M, Tamai I, Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J Pharmacol Exp Ther 2002;302:804-13
   PubMed Web of Science ®Google Scholar
• Wu J, Song Y, Li H, Chen J. Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report. Eur J Clin Pharmacol 2009;65(12):1169-74
   PubMed Web of Science ®Google Scholar
• Jacobson TA. Myopathy with statin-fibrate combination therapy: clinical considerations. Nat Rev Endocrinol 2009;5:507-18
   PubMed Web of Science ®Google Scholar
• Neuvonen PJ, Backman JT, Niemi M. Pharmacokinetic comparison of the potential over-the-counter statins simvastatin, lovastatin, fluvastatin and pravastatin. Clin Pharmacokinet 2008;47:463-74
   PubMed Web of Science ®Google Scholar
• Ehrhardt M, Lindenmaier H, Burhenne J, Influence of lipid lowering fibrates on P-glycoprotein activity in vitro. Biochem Pharmacol 2004;67:285-92
   PubMed Web of Science ®Google Scholar
• Yamazaki M, Li B, Louie SW, Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport. Xenobiotica 2005;35:737-53
   PubMed Web of Science ®Google Scholar
• Nakagomi-Hagihara R, Nakai D, Tokui T, Gemfibrozil and its glucuronide inhibit the hepatic uptake of pravastatin mediated by OATP1B1. Xenobiotica 2007;37:474-86
   PubMed Web of Science ®Google Scholar
• Park JW, Siekmeier R, Lattke P, Pharmacokinetics and pharmacodynamics of fluvastatin in heart transplant recipients taking cyclosporine A. J Cardiovasc Pharmacol Ther 2001;6:351-61
   PubMedGoogle Scholar
• Hedman M, Neuvonen PJ, Neuvonen M, Pharmacokinetics and pharmacodynamics of pravastatin in pediatric and adolescent cardiac transplant recipients on a regimen of triple immunosuppression. Clin Pharmacol Ther 2004;75:101-9
   PubMed Web of Science ®Google Scholar
• Hermann M, Asberg A, Christensen H, Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients. Clin Pharmacol Ther 2004;76:388-91
   PubMed Web of Science ®Google Scholar
• Simonson SG, Raza A, Martin PD, Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clin Pharmacol Ther 2004;76:167-77
   PubMed Web of Science ®Google Scholar
• Leier I, Jedlitschky G, Buchholz U, The MRP gene encodes an ATP-dependent export pump for leukotriene C4 and structurally related conjugates. J Biol Chem 1994;269:27807-10
   PubMed Web of Science ®Google Scholar
• Yamazaki M, Li B, Louie SW, Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport. Xenobiotica 2005;35:737-53
   PubMed Web of Science ®Google Scholar
• Treiber A, Schneiter R, Häusler S, Bosentan is a substrate of human OATP1B1 and OATP1B3: inhibition of hepatic uptake as the common mechanism of its interactions with cyclosporin A, rifampicin, and sildenafil. Drug Metab Dispos 2007;35:1400-7
   PubMed Web of Science ®Google Scholar
• Kajosaari LI, Niemi M, Neuvonen M, Cyclosporine markedly raises the plasma concentrations of repaglinide. Clin Pharmacol Ther 2005;78:388-99
   PubMed Web of Science ®Google Scholar
• Bogman K, Peyer AK, Török M, HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br J Pharmacol 2001;132:1183-92
   PubMed Web of Science ®Google Scholar
• Chen C, Mireles RJ, Campbell SD, Differential interaction of 3-hydroxy-3-methylglutaryl-coa reductase inhibitors with ABCB1, ABCC2, and OATP1B1. Drug Metab Dispos 2005;33:537-46
   PubMed Web of Science ®Google Scholar
• Matsushima S, Maeda K, Kondo C, Identification of the hepatic efflux transporters of organic anions using double-transfected Madin-Darby canine kidney II cells expressing human organic anion-transporting polypeptide 1B1 (OATP1B1)/multidrug resistance-associated protein 2, OATP1B1/multidrug resistance 1, and OATP1B1/breast cancer resistance protein. J Pharmacol Exp Ther 2005;314:1059-67
   PubMed Web of Science ®Google Scholar
• Hirano M, Maeda K, Shitara Y, Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 2004;311:139-46
   PubMed Web of Science ®Google Scholar
• Hsiang B, Zhu Y, Wang Z, A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J Biol Chem 1999;274:37161-8
   PubMed Web of Science ®Google Scholar